| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (1MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-777954
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.77795
; Jeffery, Katie ; Juszczak, Edmund ; Knight, Marian ; Lim, Wei Shen ; Montgomery, Alan ; Mumford, Andrew ; Rowan, Kathryn ; Thwaites, Guy ; Haynes, Richard ; Landray, Martin J. | Dokumentenart: | Artikel | ||||
|---|---|---|---|---|---|
| Open Access Art: | CC-Lizenz | ||||
| Titel eines Journals oder einer Zeitschrift: | Nature Communications | ||||
| Verlag: | Springer Nature | ||||
| Band: | 15 | ||||
| Seitenbereich: | S. 924 | ||||
| Datum: | 31 Januar 2024 | ||||
| Institutionen: | Informatik und Data Science > Fachbereich Maschinelles Lernen und Data Science > Chair for Computational Statistics (Prof. Dr. Thomas Jaki) | ||||
| Sonstige Projekte: | NIHR, MC_PC_19056, Wellcome Trust, 222406/Z/20/Z, UK Medical Research Council, MC_UU_0002/14 | ||||
| Identifikationsnummer: |
| ||||
| Stichwörter / Keywords: | Drug therapy Randomized controlled trials SARS-CoV-2 Viral infection | ||||
| Dewey-Dezimal-Klassifikation: | 000 Informatik, Informationswissenschaft, allgemeine Werke > 004 Informatik | ||||
| Status: | Veröffentlicht | ||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden: | Zum Teil | ||||
| Dokumenten-ID: | 77795 |
Zusammenfassung
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at ...

Zusammenfassung
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome.
Metadaten zuletzt geändert: 22 Sep 2025 12:55
Downloadstatistik